Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
48 hedge funds and large institutions have $211M invested in Evelo Biosciences, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 5 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
6% more capital invested
Capital invested by funds: $200M → $211M (+$11.6M)
2% more funds holding
Funds holding: 47 → 48 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.05M |
| 2 |
Millennium Management
New York
|
+$576K |
| 3 |
BlackRock
New York
|
+$536K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$323K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$226K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$6.13M |
| 2 |
AG
Artal Group
Luxembourg
|
-$873K |
| 3 |
CCM
CAAS Capital Management
New York
|
-$420K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$336K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$111K |
EVLO Hedge Fund Activity: Q3 2020 in Review
48 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q3 2020, worth a combined $211M — up 5.8% from $200M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EVLO positions and 5 closed out — a net gain of 1 holder — while 21 added to existing stakes and 11 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.05M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $6.13M sold.
- 48 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q3 2020, up from 47 in Q2 2020.
- Funds reported $211M of Evelo Biosciences, Inc. Common Stock stock for Q3 2020, up 5.8% quarter-over-quarter.
- 6 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q3 2020 and 5 closed out, a net change of +1 holder.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q3 2020 was Fidelity Investments, an estimated $2.05M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q3 2020 was EcoR1 Capital, an estimated $6.13M sold.
Based on aggregated 13F filings for Q3 2020.